patient's medical documentation from another medical center).
The patient was admitted to our department 2 years later with the goal of modifying his treatment that included insulin analogs, metformin, and glimepiride, but not risperidone. HbA 1c had been fluctuating from 5.4-6.5%. His current body weight was appropriate for his height (27%). Puberty was Tanner stage III. Lipid profile was normal. Anti-GAD antibodies were negative 0.6 IU/mL. Five days after pharmacotherapy discontinuation, a glucagon stimulation test revealed high C-peptide levels (baseline 3.1 ng/mL, 6 min after 8.9 ng/mL). In the following 2 years of observation, the HbA 1c had not exceeded 6% (42 mmol/mol) on diet treatment only. Notably, 3.5 years after the first positive results, the patient's diabetes autoantibodies assessed by the same person in the same certificated laboratory were negative (IA-2A 2.07 units/mL, ICA 0, anti-GAD 3.5 units/mL There are no data in the literature regarding significant high multiple islet antibodies that disappear without the development of type 1 diabetes. However, some studies have shown that the development of multiple islet autoantibodies is a critical step in pathogenesis and thus provides a robust and early marker for risk of disease progression (1) . The data for prevalence of positive diabetes autoantibodies in MODY2 patients are scarce and vary between publications (,1217%) (2,3). The significance of the presence of diabetes autoantibodies in these patients remains unclear.
Some MODY2 patients display peripheral insulin resistance that might result from interactions between the unbalanced glucose metabolism and susceptibility of gene(s) to low insulin sensitivity (4) . In the present case, risperidone could have prominent side effects including weight gain and hyperprolactinemia that resulted in the development of gynecomastia and an insulin-resistant state. It was reported that metformin could be an effective attenuator of risperidone-induced insulin-resistant hyperglycemia and dyslipidemia (5).
In conclusion, the positive diabetes autoantibodies can be transient in MODY2 patients and are not markers of prediabetes. It is possible that autoantibodies titers are aggravated by obesity or by other factors, such as drugs.
